GLP-1SG – 5mg
Original price was: $120.00.$70.00Current price is: $70.00.
GLP-1SG is a synthetic peptide, is designed to activate GLP-1 receptors, supporting the study of metabolic pathways for research purposes.
GOLD STANDARD GLP-1 AGONIST
The Most Studied GLP-1 Compound for Metabolic Research
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. Its extended half-life of approximately 7 days — achieved through albumin binding and DPP-4 resistance — enables convenient weekly research protocols. For scientists studying appetite regulation, glucose metabolism, and metabolic signaling, Semaglutide has become the reference standard.
- 94% homology to native human GLP-1
- Extended half-life (~7 days) supports weekly protocols
- Extensively characterized pharmacokinetic profile
- High stability for long-duration research designs
- Consistent, reproducible data across experimental models
For laboratory research use only. Not for human consumption.
MECHANISM OF ACTION
How Semaglutide Activates Metabolic Pathways
Semaglutide works through multiple complementary mechanisms. It reduces appetite and food intake via central nervous system GLP-1 receptor activation, slows gastric emptying to modulate nutrient absorption, and enhances glucose-dependent insulin secretion while suppressing glucagon release. This multi-target approach provides researchers with a comprehensive tool for metabolic studies.
- Central appetite suppression via hypothalamic signaling
- Delayed gastric emptying for nutrient timing studies
- Glucose-dependent insulin secretion enhancement
- Glucagon suppression for glycemic research
- Predictable pharmacokinetics for controlled experiments
For laboratory research use only. Not for human consumption.
RESEARCH APPLICATIONS
From Glycemic Control to Metabolic Signaling — Proven Research Utility
Semaglutide is the most extensively studied GLP-1 agonist available for research. Its well-characterized profile makes it ideal for comparative studies, baseline establishment, and mechanistic investigations. Whether exploring appetite pathways, insulin dynamics, or cardiovascular metabolic markers, Semaglutide provides the reliable foundation your research demands.
- Appetite regulation and satiety signaling
- Glucose homeostasis and insulin dynamics
- Gastric motility and nutrient absorption studies
- Cardiovascular metabolic marker research
- Comparative baseline for dual/triple agonist studies
- Long-duration protocols with weekly administration
For laboratory research use only. Not for human consumption.
The Science Behind GLP-1 Research: Why Semaglutide Remains the Gold Standard
Semaglutide has established itself as the benchmark compound for GLP-1 receptor research. With 94% sequence homology to native human GLP-1 and an extensively documented pharmacokinetic profile, it provides researchers with the reliability and reproducibility essential for rigorous scientific investigation.
What sets Semaglutide apart? Its engineered resistance to DPP-4 degradation and strong albumin binding create an extended half-life of approximately 7 days — enabling convenient weekly research protocols while maintaining consistent receptor activation throughout the experimental period.
The compound’s multi-target mechanism — spanning appetite suppression, gastric motility, insulin secretion, and glucagon regulation — makes it invaluable for comprehensive metabolic studies. Researchers can investigate individual pathways or explore how these systems interact under controlled conditions.
As newer dual and triple agonists emerge, Semaglutide serves a critical role as the reference standard for comparative research. Its well-characterized behavior provides the baseline against which next-generation compounds can be evaluated, making it essential for any laboratory studying incretin biology.
For research use only. Not for human consumption.
SCIENTIFIC LITERATURE
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
- Semaglutide. StatPearls Publishing; 2024.
CERTIFICATE
A detailed summary of the analytical profile, purity, and molecular integrity of the research-grade peptide compound.
DIREC
Be the first to review “GLP-1SG – 5mg”
Related products
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Reviews
There are no reviews yet.